NCT04449250View on ClinicalTrials.gov

Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

October 14, 2022

Study Completion Date

October 14, 2022

Conditions
Healthy Volunteers in Fed and Fasted State
Interventions
DRUG

Dexmethylphenidate

Subjects will be randomized to one of two sequences. Subjects will be dosed with 25 mg dose of CTx-1301 during each sequence. Subjects will serve as their own control.

Trial Locations (1)

66212

Dr. Vince Clinical Research, Overland Park

Sponsors
All Listed Sponsors
lead

Cingulate Therapeutics

INDUSTRY

NCT04449250 - Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects | Biotech Hunter | Biotech Hunter